Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

King Boosts Staffing To Remedy Financial Reporting "Material Weakness"

This article was originally published in The Pink Sheet Daily

Executive Summary

King is increasing the number of finance and accounting supervisory personnel to address a "material weakness" in its financial reporting processes

You may also be interested in...



CFO Lattanzi To Retire From King June 1

King CFO James Lattanzi is retiring from the pharmaceutical manufacturer effective June 1

CFO Lattanzi To Retire From King June 1

King CFO James Lattanzi is retiring from the pharmaceutical manufacturer effective June 1

Mylan's Pursuit Of King Ends; King Says It's Ready To Go It Alone

"Significant enhancements" in commercial operations and business development organizations will allow King to grow as a standalone company, the firm says. Mylan and King announce termination of their proposed merger one day before the "walk-away" date.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061773

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel